Latest News
Latest News
News & Press
Scientific Advancements
- Hesperos and UCF Researchers Develop Human iPSC-Derived Myelination Model, Enabling Investigation an24 October 2024, 8:13 pm
Hesperos and UCF Researchers Develop Human iPSC-Derived Myelination Model, Enabling Investigation and Treatment Development for Peripheral Nervous System DiseasesOctober 24, 2024 04:39 PM Eastern Daylight TimeORLANDO, Fla.--(BUSINESS WIRE)--Hesperos, a leader...
- Landmark Phase 2 study demonstrates the first successful clinical application of antifibrotic therap17 October 2024, 9:27 pm
Landmark Phase 2 study demonstrates the first successful clinical application of antifibrotic therapy for breast cancer News provided byMeCo Diagnostics Oct 17, 2024, 12:43 ET Positive study enables valuable repositioning of new antifibrotic...
- Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick20 September 2024, 2:06 pm
Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive...
- Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity T8 August 2024, 3:17 pm
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity TestingThe potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globallyAugust 08, 2024 08:45 ET| Source: Oragenics SARASOTA, Fla.,...
- Cognigenics Announces Groundbreaking Publication on shRNA Treatment for 5-HT2A Receptor Knockdown5 August 2024, 2:48 pm
Cognigenics Announces Groundbreaking Publication on shRNA Treatment for 5-HT2A Receptor KnockdownAugust 05, 2024 08:45 AM Eastern Daylight TimeSTUART, Fla.--(BUSINESS WIRE)--Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and...

